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How this fits in 
GP direct access testing for symptoms that could be indicative of cancer has previously been 
criticised for increasing testing and decreasing diagnostic yield. This systematic review did not 
support these concerns: no significant difference was found in the cancer conversion rate between 
GP direct access and specialist testing pathways. The time between test request and test 
performance was reduced and GP direct access testing achieved consistently higher GP and patient 
satisfaction. These findings are however limited by poor study quality: analysis of contemporary data 
is required to fully evaluate the effectiveness of direct access testing. 
  
Abstract 
Background. Direct access (DA) testing allows GPs to refer patients for investigation without 
consulting a specialist. The aim is to reduce waiting time for investigations and unnecessary 
appointments, enabling treatment to begin without delay.  
Aim. To establish the proportion of patients diagnosed with cancer and other diseases through DA 
testing, time to diagnosis, and suitability of DA investigations.  
Design and Setting. Systematic review assessing the effectiveness of GP DA testing in adults. 
Methods. Medline, Embase, and the Cochrane Library were searched. Where possible, study data 
was pooled and analysed quantitatively. Where this was not possible the data is presented 
narratively. 
Results. We identified 60 papers that met pre-specified inclusion criteria, most were carried out in the 
UK and were judged to be poor quality. We found no significant difference in the pooled cancer 
conversion rate between GP DA referrals and patients who first consulted a specialist for any test 
except gastroscopy. There were also no significant differences in the proportions of patients receiving 
any non-cancer diagnosis. Referrals for testing were deemed appropriate in 66.4% of those coming 
from GPs and 80.9% of those from consultants, this difference was not significant. The time from 
referral to testing was significantly shorter for patients referred for DA tests. Patient and GP 
satisfaction with DA testing was consistently high. 
Conclusion. GP DA testing performs as well as, and on some measures better than, consultant 
triaged testing on measures of disease detection, appropriateness of referrals, interval from referral to 
testing, and patient and GP satisfaction. 
   
Introduction 
In the United Kingdom, general practitioners (GPs) have historically acted as gatekeepers to 
secondary care and specialist testing. Gatekeeping may cause diagnostic delay in three ways: 1) 
patients may be discouraged from presenting symptoms because they suspect the GP will not take 
action; 2) GPs may fail to investigate the presenting symptoms appropriately, sometimes because 
they have no access to the relevant diagnostic tests; 3) GPs may adopt, or be obligated by 
established clinical pathways to adopt, too high a risk threshold for referral, choosing to watch and 
wait inappropriately, and only acting on red-flag late-stage symptoms.1-6 “Double gate-keeping” further 
lengthens delay when a GP must first refer the patient to a specialist who reviews the patient again 
before requesting further investigation.5   
Direct access (DA) testing allows GPs to refer patients for diagnostic testing without referring to  - or 
consulting with - a specialist first.7 It has the potential to reduce the number, cost and inconvenience 
of outpatient appointments and reduce the interval between a patient presenting to primary care and a 
diagnosis being reached (the diagnostic interval).8,9 This also has the potential to allow GPs a degree 
of freedom in which patients they refer for investigations, providing a route to investigation for patients 
whose symptoms may not trigger investigation as recommended by guideline criteria or about whom 
the GP has a ‘gut-feeling’ that investigation is warranted.10 Specialists, however, caution that capacity 
for secondary care investigation is limited and that DA leads to over-investigation without increased 
diagnostic yield.11  Conversely GP reluctance to take on responsibility for investigation has been 
demonstrated in the contexts of knee imaging and infertility12,13 and GPs often fail to employ 
diagnostic tests for cancer despite having DA to them.14  
The UK Department of Health invested £200m in 2012 to enhance GP access to four diagnostic tests 
for cancer as part of its commitment to save 10,000 lives lost due to late cancer diagnosis by 2015.15-
17 The tests chosen were non-obstetric ultrasound (ovarian cancer), flexible sigmoidoscopy (colorectal 
cancer) and magnetic resonance imaging (MRI) (brain cancer); it was also proposed to improve open-
access to chest x-rays  - where there were often significant reporting delays - to expedite diagnosis of 
lung cancer.15,18 In 2015, the National Institute for Health and Care Excellence (NICE) guidelines for 
suspected cancer recommended that GPs had direct and rapid access to laboratory tests (Ca125, 
faecal occult blood testing, full blood count), ultrasound and radiology (x-ray, computed tomography 
(CT), MRI), and endoscopy of the gastro-intestinal (GI) tract for patients who do not meet the criteria 
for an urgent referral to a specialist but who do have symptoms warranting urgent investigation in 
specific clinical scenarios.19 At that time, a survey of GPs showed that investment was required to 
achieve DA to these tests across all English regions in order to reduce the intervals between request, 
testing, and reporting.20 GPs reported good access to x-ray and laboratory investigations - apart from 
faecal occult blood testing and urine protein electrophoresis - whilst two thirds had DA to gastroscopy, 
half to CT, and one third to colonoscopy. Excluding x-ray, less than one fifth of GPs could access 
radiology and endoscopy within the timescales recommended by NICE.  
 
We aimed to systematically review the evidence for DA testing of adults presenting to primary care, 
reporting the proportion of patients diagnosed with cancer or another diagnosis (the conversion rate), 
and where possible the indications for testing, time to testing, appropriateness and acceptability to 
GPs, specialists, and patients. Where reported, we include direct comparisons with outcomes in 
patients from the same population triaged by a specialist before testing. To our knowledge, there has 
been no published systematic review of this type to date. 
Methods 
Search 
We registered the systematic review protocol with PROSPERO21  and conducted a comprehensive 
search of the following electronic databases: MEDLINE, Embase, and the Cochrane Library. The 
search strategy was adapted according to the requirements of the databases and is reported in 
Appendix 1. In brief, the key search terms were as follows: 
- Direct, open, rapid, or one-stop diagnosis or investigations. 
- Primary health care, general practitioner, general practice, family doctor, or specialist referral. 
- Cancer, neoplasm, or carcinoma. 
 We included all study types except case studies and case series. We included adults (18yrs and 
older) attending primary care and undergoing DA testing where cancer could be an outcome. DA 
testing was defined as a test that a GP could access without consulting with a specialist first. Where 
reported we included data from “specialist” comparator groups. These patients either underwent 
specialist triage, where tests requested by a GP were first screened by a specialist to determine 
whether the patient was appropriate for testing, or underwent specialist testing, where tests were 
requested by a specialist after they reviewed the patient in clinic. In addition to the database search, 
the reference lists of identified reviews and included studies were checked for additional papers 
meeting our inclusion criteria. Finally, a ’related articles’ search was performed in PubMed on all 
included studies. No language or time limits were placed on the searches.  
Data Extraction 
The titles and abstracts of all retrieved articles were screened independently by two reviewers (BN 
and AT) and any disagreements were resolved through discussion. The full text of the remaining 
articles were read by two reviewers independently. Four initial screening questions were used for 
each paper: 1) Open/DA confirmed (Y/N) – if no, exclude; 2) Specialist triage of referrals (Y/N) – If 
yes, exclude; 3) GP DA referral outcome data reported separately? (Y/N) – if no, exclude; 4) Cancer 
diagnosis possible? (Y/N) – if no, exclude. Retained studies went on to full text review and data 
extraction by two independent reviewers. Data was extracted into a pre-prepared Excel spreadsheet, 
compared, and if necessary any disagreements were resolved by a third reviewer (CFS). 
Quality assessment 
The risk of bias and quality of the studies was assessed by two reviewers independently. 
Disagreements regarding the risk of bias in individual studies was resolved through discussion, with 
the involvement of a third reviewer if necessary. The Newcastle-Ottawa tool was used to review 
observational studies and the Cochrane Risk of Bias tool was used to assess the risk of bias in 
randomised controlled trials. The results of the quality assessment are used to provide an overall 
assessment of the quality of the included studies and no studies were excluded on quality alone. 
Analysis 
The primary outcome of interest was the number of cancers diagnosed by DA or specialist testing, 
recorded as the absolute number and expressed as the cancer conversion rate (CR). The CR is the 
number of cancer cases expressed as a proportion of all patients attending DA testing. Secondary 
outcomes of interest were non-cancer diagnoses (with corresponding CR), indications for testing, time 
to diagnosis, the appropriateness of referral determined by local, national or international guidelines, 
and measures of GP, specialist, and patient acceptability.  
CRs were calculated for cancer and non-cancer diagnoses for each study, grouped by test type, and 
pooled to give a CR for each test. Pooled estimates were calculated in Stata where appropriate using 
the metaprop command, weighted using the Freeman-Tukey double arcsine transformation to allow 
for variation in sample sizes, for: the CR of each DA test; subgroups of studies reporting DA testing in 
relation to a specialist comparator group; and to summarise appropriateness.22,23 The Wilcoxon-
Mann-Whitney test was used to investigate whether GP DA reduced the interval from referral to 
diagnostic test and referral to diagnosis. In addition, a narrative review of patient and GP satisfaction 
was conducted.  
Results  
The PRISMA flow diagram in Figure 1 outlines the selection of the 60 studies included in the review.  
[Figure 1 about here] 
Table 1 describes the papers included. There were 34 cross-sectional studies, 24 cohort studies, a 
randomised controlled trial, and a non-randomised trial. Gastroscopy was the most commonly studied 
DA test (27 studies),24-50 followed by lower GI endoscopy (proctoscopy, flexible sigmoidoscopy or 
colonoscopy, 15 studies),51-65 CT (3 studies – 2x head, 1x chest),66-68 ultrasound (3 studies – 2x 
abdominal, 1x gynaecological),69-71 MRI (3 studies),72-74 x-ray (2 studies),75,76 gastroscopy and lower 
endoscopy combined (2 studies),77,78 mammogram (1 study),79 mammogram and ultrasound 
combined (1 study),80 MRI and CT combined (1 study),81,82 transvaginal sonography (1 study),83 and a 
range of radiological tests including MRI, CT and barium meal (1 study).84 Fifty-seven studies (95%) 
reported DA testing performed in a hospital or specialist clinic setting, one utilised a DA test located in 
primary care29 and two did not specify location.54,77 
[Table 1 about here] 
Quality Assessment 
The overall quality of the studies included in this review was poor. The majority (49, 82%) of studies 
included a representative sample of consecutive patients. However, thirty-nine studies (65%) 
demonstrated attrition of patients between inclusion and reporting outcomes without adequate 
explanation of why. Most (54, 90%) assessed patient outcomes through linked clinical records. Only 
one paper justified the sample size.33 The vast majority of studies (56, 93%) presented a descriptive 
analysis without testing for significance between subgroups and nine studies (15%) justified the 
statistical method used. 
Gastroscopy 
Twenty-three studies reported data allowing cancer CR to be calculated for DA gastroscopy. 
Indication for testing was left to the GPs’ discretion in 11 (41%) studies; five studies (19%) included 
only patients with dyspepsia; four required no previous gastroscopy (15%); one required no prior 
gastroenterological referral; one followed British Society of Gastroenterology gastroscopy guidance, 
and one stipulated specific alarm symptoms (Appendix 2). 
The cancer CR ranged from 0% to 7.2% (pooled 1.7%, 95% confidence interval (CI) 1.2 to 2.2%, 
appendix 2) and the non-cancer CR ranged from 11.8 to 98.7% (56.9%, 95%CI 44.1 to 69.2%, 
appendix 3). When restricted to the eight studies including a specialist comparator group, the DA 
cancer CR ranged from 1.2 to 2.2% (pooled 1.6%, 95%CI 1.3 to 1.9%) and the specialist cancer CR 
ranged from 1.0% to 5.1 % (pooled 2.7%, 95% CI 1.8 to 3.7, p=0.03); the DA non-cancer CR ranged 
from 50.7% to 98.7% (pooled 66.6%, 95%CI 52.6 -79.3%) and the specialist testing non-cancer CR 
ranged from 44.2% to 99.0% (pooled 63.2%, 95%CI 51.6 – 74.0%, p=0.70).  
Large bowel endoscopy. 
Ten studies reported data allowing the calculation of cancer and other disease CR for large bowel 
endoscopy, the indication for testing was left to the GPs discretion in five studies (50%). The 
remainder specified a range of age and symptom criteria, most commonly rectal bleeding, anaemia, 
and change in bowel habit (Appendix 4). 
The cancer CR ranged from 1.7% to 11.1% (pooled 4.5%, 95% CI 3.4 to 5.7%) and the non-cancer 
diagnosis CR ranged from 28.8% to 62.5% (pooled 46.5%, 95% CI 35.5% - 57.6%) (Appendix 4 and 
5). When restricted to the four studies including a specialist comparator group, the DA cancer CR 
ranged from 3.6-10.8% (pooled 5.4%, 95% CI 3.5 to 7.6%) and the specialist cancer CR ranged from 
0.9% to 7.0% (pooled 3.0%, 95% CI 1.6 to 4.6, p=0.06). The DA non-cancer CR in these four studies 
ranged from 40.3% to 62.5% (pooled 50.3%, 95% CI 40.0 -60.6%) and the specialist non-cancer CR 
ranged from 28.4 to 64.9% (pooled 47.5%, 95% CI 32.0 – 63.2%, p=0.77).  
Other tests 
Across the remaining 14 studies reporting data to allow the calculation of cancer and other diagnoses 
CR, the cancer CR ranged from 0.0% for transvaginal sonography for abnormal vaginal bleeding to 
11.7% in a study reporting a wide range of DA tests used at the GPs’ discretion (Appendix 6).83,84 The 
conversion rate for non-cancer diagnosis ranged from 4.2% for patients undergoing mammogram to 
56.4% in a study reporting the use of DA x-ray used at the GPs’ discretion (Appendix 7).76,79 As there 
were few studies reporting each test type, and test types were heterogeneous, results were not 
pooled. A summary of the cancer CR and non-cancer CR for all test types is in Table 2. 
[Table 2 about here] 
Appropriateness of referral 
Nine studies reported the appropriateness of test requests using guidelines from the American 
Society for Gastrointestinal Endoscopy,25,59,77,78 the European Panel of the Appropriateness of 
Gastrointestinal Endoscopy,52,56 the British Society of Gastroenterology,26 NICE,27 and previously 
published work.29 Overall, there was no significant difference between the appropriateness of GP DA 
referrals (mean pooled appropriateness 66.4%, 95% CI 41.2 – 87.4%) and specialist referrals (mean 
pooled appropriateness 80.9, 95% CI 73.9 – 87.1) (p=0.24).  
Time to test and diagnosis 
Specialist referrals resulted in a significantly longer interval between referral and testing (mean = 76.6 
days, S.D. 48.0 days) compared to GP DA referrals (mean = 31.9 days, S.D. 20.5 days) (z=2.0, 
p=0.03, 9 studies). There was no significant difference, however, in the interval between GP DA 
(mean = 74.0 days, S.D. 15.6 days) and specialist referral (mean = 59.5 days, S.D. 21.9 days) and 
final diagnosis (z=-0.78, p=0.44, 2 studies).  
Patient and GP satisfaction 
Three studies reported patient satisfaction with DA endoscopy and sigmoidoscopy of over 90%.53,55,57 
One study reported over 90% patient satisfaction with the time from referral to test and the test to 
receiving results, and the majority of patients felt that seeing a specialist first or receiving test results 
from a specialist was not necessary.57  
Two studies reported on GPs’ satisfaction with DA testing. One study reported that over 90% of GPs 
found DA sigmoidoscopy “useful”,34 and the other that 72% of GPs who had referred patients for DA 
MRI felt that it was good value for money, including 84% of those who had thought that DA MRI 
involved extra cost.72 
Discussion 
Summary 
In this systematic review we aimed to summarise the current evidence for GP DA testing for 
symptoms related to cancer. Our results show that overall the DA CR ranged from 0-12% for cancer 
and 4-99% for non-cancer diagnoses, dependent on the type of DA test and the indications for 
referral. Studies reporting a comparison between DA and patients seen by a specialist before testing 
showed a similar CR for both cancer and for non-cancer diagnoses and, when evaluated, no 
significant differences in the appropriateness of referrals.  
GPs and patients reported high satisfaction with DA with only one study reporting a higher number of 
GPs preferring specialist over DA referral.53 Concerns about DA testing related to the experience of 
the procedure itself, for example the discomfort of endoscopy, rather than the process of referral and 
testing. The small number of studies reporting measures of satisfaction, however, mean that these 
results should be viewed with caution.  
DA reduced the time from GP referral to testing compared to specialist referral and this may have 
contributed to the high levels of patient satisfaction reported, although no data on patient satisfaction 
with specialist referral was reported for comparison. Despite the reduction in time to test with DA, 
there was no corresponding reduction in time to diagnosis. Previous reports confirm that expedited 
testing does not necessarily lead to quicker diagnosis due to waiting lists for further investigations, 
poor communication between specialties, and misunderstandings about who is responsible for 
arranging onward referral.85 
Strengths and limitations 
We performed a comprehensive search and applied strict selection criteria to ensure we only included 
studies reporting GP DA testing. We retrieved 60 studies from 15 countries published between 1979 
and 2015, making this the largest published review on DA cancer testing. However, the majority of 
studies were judged to be poor quality: most were observational, without a comparator group, using 
retrospective clinical record review, increasing the risk of bias and limiting the external validity of our 
findings. Reporting was of poor quality, for example, a justification of the methods used was often 
missing, and some authors did not comprehensively report diagnoses if focussing on other outcomes 
such as patient satisfaction which could be strongly influenced by the final diagnosis.  
Studies reported a range of DA tests requested for a variety of clinical indications. Deriving pooled 
estimates from a heterogeneous group of studies has important limitations. For example, studies with 
different clinical indications for testing will have varying pre-test probabilities for cancer or non-cancer 
diagnoses. To minimise the effect of this limitation, we report the indications for testing and the CRs 
for each study individually. We also report CR ranges in addition to pooled estimates, stratify data by 
test type, and report separate pooled estimates when studies report outcomes for both DA and 
specialist routes with the same clinical indications. Studies describing DA gastroscopy and large 
bowel endoscopy dominated, particularly in relation to the appropriateness and acceptability of DA 
testing, and so caution is advised in the generalisation of these findings to other test types. 
The use of clinical guidelines to define the appropriateness of referral may present a further limitation. 
Guidelines, and their underpinning evidence, vary in quality and have been criticised for 
oversimplifying the complexity of primary care where undifferentiated symptoms are commonplace 
and associated with both minor illness and serious disease.86,87 They do, however, provide a standard 
of care, to improve service delivery and health outcomes against which to evaluate clinician action.88  
Comparison with literature 
Two randomised controlled trials have investigated DA testing and were not included in this review as 
they were not investigations for cancer: MRI for knee symptoms (the DAMASK trial) and 
hysterosalpingography (HSG) for infertility (the OATS trial).12,13 Both studies found no difference in 
waiting times and patient outcomes between DA and specialist referral routes. Uptake of DA testing, 
however, was low in both studies. A qualitative assessment of OATS revealed that the main barriers 
to the uptake of DA HSG were the infrequency of patients presenting for infertility investigation, lack of 
clarity over the responsibility for follow-up, and lack of support and guidance.89 DA tests to investigate 
symptoms that could indicate cancer will have greater uptake due to the higher prevalence of these 
symptoms in primary care, and since DA testing has been sanctioned by NICE in England and Wales, 
and incorporated into local referral pathways.3 
Implications for research and practice 
A common criticism of GP DA testing is that it could lead to an increase in inappropriate referrals, 
resulting in a decrease in the CR: our review suggests that these concerns are unsupported.7 Cancer 
CRs following DA testing were notably lower than the 10-11% CR reported following analysis of 
urgent (two-week-wait) cancer referrals in the UK.90,91 However, these early two-week-wait pathways, 
based on the 2005 NICE guidelines, were criticised for focussing on red-flag symptoms and being 
based on research derived from specialist care. As a result, patients with lower but not no risk 
symptoms were less likely to be referred urgently, experienced delays in diagnosis, and were more 
likely to be diagnosed with cancer as an emergency.92,93 The move to improving access to diagnostic 
testing for lower risk symptoms in the 2015 NG12 NICE guidelines was based on emerging primary 
care research.94 NG12 set a referral threshold of a 3% risk of cancer recommending combinations of 
clinical features for DA testing.95 Our review suggests that a DA strategy may achieve a CR close to 
3%, not only if the pathway entry criteria are evidence-based referral indications (similar to NG12), but 
also if the indication for referral is GP discretion alone. Detailed analysis of the outcomes of diagnostic 
pathways that have been developed in the UK to incorporate the NG12 DA criteria will greatly inform 
this debate, as will ongoing work on the investigations of non-specific cancer symptoms which, at 
present are less likely to be included as explicit guideline criteria.96 
This review has re-emphasised the importance of whole pathway redesign and the need to focus 
efforts to reduce diagnostic delay on all intervals between symptomatic presentation to GP and final 
diagnosis: DA may be successful in reducing the time to test but no difference was found in the total 
diagnostic interval.97,98 Post-testing delays could balance out gains made by a DA strategy in the pre-
test period if resources are not also invested in reducing the time between testing, reporting, definitive 
diagnosis and treatment. Time spent waiting, whether for testing or treatment, has been identified as 
an important component in the satisfaction of cancer patients.3,99,100 Improving the pathway to 
diagnosis for patients with non-specific symptoms may be achieved by national programmes in the 
UK such as Accelerate Coordinate and Evaluate (ACE) and the Danish “three legged strategy” which 
are investigating the role of Multi-Diagnostic Centre based pathways for patients with non-specific 
symptoms of cancer that fall outside of current urgent referral pathways.101-103 
In conclusion, this study provides the first overview of the literature on GP DA testing for symptoms 
that could represent cancer. It suggests that DA testing at the discretion of the GP may not result in a 
significant decrease in the proportion of patients diagnosed with cancer or other non-cancer 
pathology. It supports the increase in DA testing included in the UKs 2015 NICE guidelines. Patients 
and GPs show high satisfaction with DA testing, but our results highlight the need for better quality 
contemporary evidence on the optimal DA testing strategy to ensure a balance is achieved between 
primary care testing and disease detection.  
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